Giredestrant is undergoing a broad clinical development program; in addition to the heredERA BC study, it is also being investigated as a potential endocrine backbone therapy of choice in several phase III trials of patients with ER+, HER2– BC in the early and metastatic settings. The gene discussed is ESR1; the disease is breast cancer.